Products for Research Use Only
RegisterLogin

Revumenib

CAT: 0804-HY-136175-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-136175-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) [1].
CAS Number
2169919-21-3
Product Name Alternative
SNDX-5613
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/revumenib.html
Purity
99.99
Solubility
DMSO : ≥ 25 mg/mL
Smiles
O=C(N(CC)C(C)C)C1=CC(F)=CC=C1OC2=CN=CN=C2N3CC4(CCN(C[C@H]5CC[C@H](NS(=O)(CC)=O)CC5)CC4)C3
Molecular Formula
C32H47FN6O4S
Molecular Weight
630.82
Precautions
H302, H315, H319
References & Citations
[1]A drug, SNDX-5613, to treat acute leukemia with a KMT2A translocation or an NPM1 mutation that has come back (relapsed) or has not gotten better with treatment (refractory) .
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched

Alternative Products

CatalogName
C8689-10Revumenib
T202855-01Revumenib Citrate
S8996-5mgRevumenib (SNDX-5613)
C21534-1gSNDX-5613 (Revumenib)
A22526-2Revumenib (SNDX-5613) 2mg
A22526-25Revumenib (SNDX-5613) 25mg
A22526-1Revumenib (SNDX-5613) 1mg
A22526-10mM-DRevumenib (SNDX-5613) 10mM * 1mL in DMSO

Popular Products